Allogene Therapeutics Inc (ALLO)

Jul 26, 2026

ALLO|Allogene Therapeutics Inc|Price:1.740|Chg%:-0.080 - TradingKey

Jul 26, 2026

Jul 26, 2026

Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 26, 2026

Jul 25, 2026

Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO - TradingView

Jul 25, 2026

Jul 24, 2026

ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits

Jul 24, 2026

Jul 24, 2026

Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026

Jul 16, 2026

Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO) - The Globe and Mail

Jul 16, 2026

Jul 15, 2026

Allogene reports 31% response rate in renal cancer trial By Investing.com - Investing.com South Africa

Jul 15, 2026

Jul 15, 2026

Allogene Therapeutics (ALLO) Unveils Promising Phase 1 Study Res - GuruFocus

Jul 15, 2026

Jul 15, 2026

Allogene reports 31% response rate in renal cancer trial - Investing.com

Jul 15, 2026

Jul 15, 2026

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors - The Manila Times

Jul 15, 2026

Jul 15, 2026

Allogene Therapeutics Announces Journal of Clinical - GlobeNewswire

Jul 15, 2026

Jul 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 15, 2026

Jul 13, 2026

Allogene Therapeutics (ALLO) Q3 2024 earnings summary - Quartr

Jul 13, 2026

Jul 13, 2026

Allogene Therapeutics (ALLO) Proxy filing Summary - Quartr

Jul 13, 2026

Jul 11, 2026

Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN

Jul 11, 2026

Jul 09, 2026

Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution - The Business Journals

Jul 09, 2026

Jul 06, 2026

Form 4 Allogene Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Jul 06, 2026

Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs - Stock Titan

Jul 06, 2026

Jul 06, 2026

Allogene Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Roberts Zachary - Moomoo

Jul 06, 2026

Jul 04, 2026

Allogene Therapeutics shows promise with ALPHA3 trial and ALLO-329, cutting losses and extending cash runway. - Pluang

Jul 04, 2026

Jul 04, 2026

Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO) - Seeking Alpha

Jul 04, 2026

Jul 02, 2026

ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill

Jul 02, 2026

Jun 30, 2026

Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Nigeria

Jun 30, 2026

Jun 28, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 28, 2026

Jun 28, 2026

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

Jun 27, 2026

Jun 26, 2026

Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView

Jun 26, 2026

Jun 25, 2026

Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN

Jun 25, 2026

Jun 25, 2026

ALLO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 25, 2026

Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union

Jun 25, 2026

Jun 25, 2026

Allogene Therapeutics (ALLO) Edges Higher Near Key Resistance LevelInsider Selling Alerts - dars.gov.et

Jun 25, 2026

Jun 24, 2026

Recent pharma exec shake-ups signal strategic shifts - Pharma Voice

Jun 24, 2026

Jun 23, 2026

Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan

Jun 23, 2026

Jun 23, 2026

[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 23, 2026

Jun 23, 2026

Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan

Jun 23, 2026